Abstract
Objective: Antipsychotic drugs are known to increase mortality among patients with dementia. Many patients receive concomitant treatment with other psychotropic agents. The aim of this retrospective cohort study was to investigate the impact of benzodiazepines and antidepressants on the risk of death in patients with dementia initiating antipsychotic drug treatment. Methods: Nationwide registry data on all incident dementia cases among individuals aged 65 years and older in Denmark between 2009 and 2013 for which antipsychotic treatment was initiated were used. The 180-day mortality was evaluated by crude and adjusted hazard ratios (HRs, including adjustment for somatic and psychiatric comorbidity, other prescription drugs, nursing home residency, and time since diagnosis), comparing periods of antipsychotic treatment with periods of concomitant treatment with benzodiazepines or antidepressants. Results: Among 41,494 incident dementia cases, antipsychotic treatment was initiated for 10,291 (24.8%). After 3,140 people were excluded due to recent antipsychotic drug use or hospitalization, 7,151 people were included in the analysis. The total follow-up time during current antipsychotic treatment was 1,146 person-years, and 831 died during antipsychotic treatment. Compared with antipsychotic treatment alone, the risk of death increased during antipsychotic treatment in combination with benzodiazepines (adjusted HR = 2.19; 95% CI, 1.83-2.63), while there was a decreased risk of death during antipsychotic treatment in combination with antidepressants (adjusted HR = 0.61; 95% CI, 0.50-0.74). Conclusions: The diverse impact of concomitant use of benzodiazepines and antidepressants on mortality may be due to a direct drug-related effect. Alternatively, the findings could reflect differential mortality associated with different indications for therapy. Although the results cannot prove causality, and there may be residual confounding, clinicians should be cautious when considering the combination of antipsychotics and benzodiazepines in patients with dementia.
| Original language | English |
|---|---|
| Article number | 19m12828 |
| Journal | Journal of Clinical Psychiatry |
| Volume | 81 |
| Issue number | 4 |
| ISSN | 0160-6689 |
| DOIs | |
| Publication status | Published - 2020 |
Funding
Submitted: March 13, 2019; accepted December 3. Nørgaard A, Jensen-Dahm C, Gasse C, et al. drugs among elderly patients. CMAJ. 17, 2019. Time trends in antipsychotic drug use in 2007;176(5):627–632.PubMed Publishedonline:June 2, 2020. patients with dementia: a nationwide study. 12. Johnell K, Jonasdottir Bergman G, Fastbom J, J Alzheimers Dis. 2016;49(1):211–220.PubMed CrossRef et al. Psychotropic drugs and the risk of fall Potential conflicts of interest:The authors have no 4. Huybrechts KF, Rothman KJ, Silliman RA, et al. injuries, hospitalisations and mortality among potentialconflictsofinteresttodeclare. Risk of death and hospital admission for major older adults. Int J Geriatr Psychiatry. Funding/support:The Danish Dementia Research medical events after initiation of psychotropic 2017;32(4):414–420.PubMed CrossRef Centre is supported by grants from the Danish medications in older adults admitted to Thygesen LC, Daasnes C, Thaulow I, et al. Ministry of Health (file no. 2007-12143-112/59506 nursing homes. CMAJ. 2011;183(7):E411–E419.PubMed Introduction to Danish (nationwide) registers and file no. 0901110/34501). Dr Nørgaard was Gill SS, Bronskill SE, Normand SL, et al. on health and social issues: structure, access, funded by the Research Fund of Rigshospitalet, Antipsychotic drug use and mortality in older legislation, and archiving. Scand J Public Health. Copenhagen University Hospital, Copenhagen, adults with dementia. Ann Intern Med. 2011;39(7 suppl):12–16.PubMed CrossRef Denmark. 2007;146(11):775–786.PubMed CrossRef Ray WA. Evaluating medication effects outside Roleofthesponsor:Thefundingorganizations 6. Kales HC, Valenstein M, Kim HM, et al. Mortality of clinical trials: new-user designs. Am J had no role in the design and conduct ofthe risk in patients with dementia treated with Epidemiol. 2003;158(9):915–920.PubMed CrossRef study;collection,management,analysis,and antipsychotics versus other psychiatric Rikala M, Hartikainen S, Saastamoinen LK, et al. interpretation ofthe data; preparation, review, or medications. Am J Psychiatry. Measuring psychotropic drug exposures in approval ofthe manuscript; and decision to submit 2007;164(10):1568–1576, quiz 1623.PubMed CrossRef register-based studies—validity of a dosage the manuscript for publication. 7. Schneider LS, Dagerman KS, Insel P. Risk of assumption of one unit per day in older Finns. death with atypical antipsychotic drug Int J Methods Psychiatr Res. 2013;22(2):155–165.PubMed CrossRef Supplementarymaterial:Available at treatment for dementia: meta-analysis of Charlson ME, Pompei P, Ales KL, et al. A new PSYCHIATRIST.COM. randomized placebo-controlled trials. JAMA. method of classifying prognostic comorbidity 2005;294(15):1934–1943.PubMed CrossRef in longitudinal studies: development and 8. Hajjar ER, Hanlon JT, Artz MB, et al. Adverse validation. J Chronic Dis. 1987;40(5):373–383.PubMed CrossRef drug reaction risk factors in older outpatients. Sundararajan V, Henderson T, Perry C, et al. Barnes TRE, Banerjee S, Collins N, et al. Am J Geriatr Pharmacother. 2003;1(2):82–89.PubMed CrossRef New ICD-10 version of the Charlson Antipsychotics in dementia: prevalence and 9. Nørgaard A, Jensen-Dahm C, Gasse C, et al. comorbidity index predicted in-hospital qualityofantipsychoticdrugprescribinginUK Psychotropic polypharmacy in patients with mortality. J Clin Epidemiol. mental health services. Br J Psychiatry. dementia: prevalence and predictors. 2004;57(12):1288–1294.PubMed CrossRef 2012;201(3):221–226.PubMedCrossRef J Alzheimers Dis. 2017;56(2):707–716.PubMed CrossRef Schneeweiss S, Seeger JD, Maclure M, et al. Martinez C, Jones RW, Rietbrock S. Trends in 10. Pasqualetti G, Tognini S, Calsolaro V, et al. Performance of comorbidity scores to control the prevalence of antipsychotic drug use Potential drug-drug interactions in Alzheimer for confounding in epidemiologic studies among patients with Alzheimer’s disease and patients with behavioral symptoms. Clin Interv using claims data. Am J Epidemiol. other dementias including those treated with Aging. 2015;10:1457–1466.PubMed 2001;154(9):854–864.PubMed CrossRef antidementia drugs in the community in the Schneeweiss S, Setoguchi S, Brookhart A, et al. Wang PS, Schneeweiss S, Avorn J, et al. Risk of UK: a cohort study. BMJ Open. Risk of death associated with the use of death in elderly users of conventional vs 2013;3(1):e002080.PubMed CrossRef conventional versus atypical antipsychotic atypical antipsychotic medications. N Engl J
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS